Chong Kun Dang Holdings (001630) Fundamentals 2026 — P/E 3.0x, Revenue Analysis | SniperIQ
Chong Kun Dang Holdings (001630) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩178.5B, trading at ₩37500.00 on the KSC. This SniperIQ fundamentals page covers Chong Kun Dang Holdings's valuation (P/E 3.0x, P/B 0.3x), profitability (net margin 5.0%), revenue (₩959.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Chong Kun Dang Holdings's market cap?
Chong Kun Dang Holdings (001630) has a market capitalization of approximately ₩178.5B, trading at ₩37500.00 on the KSC. Market cap moves with the live share price.
What is Chong Kun Dang Holdings's P/E ratio?
Chong Kun Dang Holdings's trailing twelve-month P/E ratio is 3.0x, with a price-to-book (P/B) of 0.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Chong Kun Dang Holdings?
Chong Kun Dang Holdings runs a net profit margin of 5.0%, a gross margin of 43.3%, and an operating margin of 6.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Chong Kun Dang Holdings generate?
Chong Kun Dang Holdings reported revenue of ₩959.0B for fiscal year 2025, with net income of ₩40.4B and earnings per share (EPS) of 8492.65. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Chong Kun Dang Holdings pay a dividend?
Chong Kun Dang Holdings offers a trailing dividend yield of about 3.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Chong Kun Dang Holdings financially healthy?
Chong Kun Dang Holdings carries a debt-to-equity ratio of 0.88x and a current ratio of 0.83x, with a market beta of 0.53. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Chong Kun Dang Holdings a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Chong Kun Dang Holdings (001630) the key facts are: market cap ₩178.5B, P/E 3.0x, revenue ₩959.0B, 52-week range 36400-59300. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Chong Kun Dang Holdings's full fundamentals live
Get Chong Kun Dang Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.